|
|
||||||||

Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20910, USA
Correspondence
Michael J. Brennan
mbrennan{at}aeras.org
| ABSTRACT |
|---|
|
|
|---|
Present address: Aeras Global TB Vaccine Foundation, 1405 Research Boulevard, Suite 300, Rockville, MD 20850, USA.
A table of primers and a supplementary figure are available with the online version of this paper.
| INTRODUCTION |
|---|
|
|
|---|
In this study, we chose to compare three PE_PGRS members, PE_PGRS 16, PE_PGRS 26 and PE_PGRS 33, since there is some previous evidence that genetic variation can occur in these genes (Talarico et al., 2005
, 2008
) and that their expression may be regulated by different mechanisms (Dheenadhayalan et al., 2006b
). PE_PGRS 26 was chosen for comparison since it represents a typical member of more than 60 PE_PGRS family members in both sequence and size while PE_PGRS 16 is representative of a small subset of PE_PGRS members which carry a unique domain linked at the C terminus to the PGRS domain. PE_PGRS 33 is one of the most extensively studied PE_PGRS proteins (Brennan et al., 2001
; Delogu et al., 2004
; Dheenadhayalan et al., 2006a
; Basu et al., 2007
; Balaji et al., 2007
) and we used it to compare with the other two family members. Mycobacterium smegmatis strains expressing the PE_PGRS proteins were used to investigate the host response of macrophages and mice to infectivity with these strains and the effect of the PE_PGRS expression on the mycobacteria and the host cells. M. smegmatis is a non-pathogenic fast-growing soil saprophyte that lacks PE_PGRS proteins. Hence it serves as a good model system to study the role of specific PE_PGRS proteins via construction of recombinant strains. Comparative studies on the three PE_PGRS antigens were also performed to determine if they may be useful targets for developing vaccines against tuberculosis (TB).
| METHODS |
|---|
|
|
|---|
Quantitative real-time PCR.
Total RNA was extracted from mycobacterial cultures or from mouse organ homogenates using a RNeasy minikit (Qiagen). Briefly, mouse organs were macerated in DMEM and centrifuged. The pellet was resuspended in Ack RBC lysis buffer followed by washes with DMEM. The pellet was finally resuspended in RLT buffer supplemented with β-mercaptoethanol and the lysate was passed through a 20 gauge needle fitted to an RNase-free syringe five times for homogenization. One volume of 70 % ethanol was added to the lysate and a sample was loaded onto the RNeasy colum. This was followed by washes with buffers RW1 and RPE from the kit and the RNA was eluted with RNase-free water. After quantification, RNA samples were treated with DNase I (Invitrogen) and subjected to cDNA synthesis using the Superscript First-Strand Synthesis system for RT-PCR (Invitrogen), following the manufacturer's instructions. Quantitative expression of the pe_pgrs genes and 16S rRNA gene was performed by real-time PCR using Cepheid's real-time PCR smart cycler. PCR was performed in a 25 µl reaction volume containing 12.5 µl 2x Real-time Premix ExTaq from TaKaRa, each primer pair and Taqman probe at a concentration of 0.5 µM. Samples were subjected to an initial step of 50 °C for 2 min and subsequent denaturation at 95 °C for 5 min. This was followed by 40 cycles each of 95 °C for 15 s and 60 °C for 1 min. Each reaction was performed in triplicate and the mean threshold cycle (Ct) was determined for each sample and plotted against the cDNA concentration input to calculate the slope. Amplification efficiency was then calculated using the formula E=10(–1/slope) (Pfaffl, 2001
). All PCRs were performed with equal efficiencies; hence relative mRNA expression levels of pe_pgrs genes were directly normalized against 16S rRNA expression using the formula
, where
Ct=(Ct target gene)–(Ct reference gene).
Transfections and immunoblotting.
For transfection of eukaryotic cells with nucleic acid-based constructs, human rhabdomyosarcoma cells were seeded in 24-well plates at a density of 1.5x105 per well. The following day, lipofectamine 2000 (Invitrogen) was used to transfect cells with 1 µg of the different pe_pgrs constructs in the mammalian expression vector pJW4303, following the manufacturer's recommendations and using the vector as a control. After 6 h the transfection mixture was removed and replaced with fresh growth medium. Protein expression was monitored after 24 h by 10 % SDS-PAGE and immunoblotting. PE_PGRS proteins were detected using a recently established anti-PE_PGRS mAb, 7C4.IF7, which will be described in more detail elsewhere (M. Parra and others, unpublished results) or mouse sera diluted in PBS-milk as the primary antibodies; alkaline phosphatase conjugated goat anti-mouse IgG was used as secondary antibody. The blots were developed using the colorimetric substrate NBT/BCIP (KPL). For immunofluorescence studies, the anti-PE_PGRS mAb 7C4.IF7 and goat anti-mouse antibody conjugated to Alexafluor 488 were used as primary and secondary antibody, respectively, and photographs at a final magnification of x1000 were taken with a Nikon Optiphot-2 microscope equipped with a digital camera and using the FITC-GFP channel adjusted with phase-contrast to show the fluorescence superimposed on the background of mycobacteria.
Infection of murine bone marrow macrophages (BMMO) with recombinant M. smegmatis..
BMMO were isolated from femurs of healthy C57BL/6 J mice and cultured in complete DMEM as previously described (Delogu & Brennan, 2001
). Macrophages were infected with vector pMV261Nde-I and different recombinant M. smegmatis strains at a m.o.i. of 5 : 1 (bacteria : macrophage). A few wells containing coverslips were used for Giemsa staining to visualize cytoplasmic and nuclear details microscopically following infection. At various time points (4 h and days 3, 6 and 10), the culture supernatants were collected and stored at –80 °C for in vitro tests. The BMMO were then washed once with PBS to remove extracellular bacteria, lysed in 0.1 % saponin (Sigma) by incubating for 3 min at room temperature, serially diluted in PBS containing 0.05 % Tween 80 and plated on Middlebrook 7H11 agar (Difco) plates supplemented with 10 % OADC and 50 µg hygromycin B ml–1. Colony forming units (c.f.u.) were determined as a measure of the intracellular survival of recombinant M. smegmatis. Statistical analyses were performed using a one-way analysis of variance, and significant differences (including determination of P values) between the means were measured by Tukey's test using GraphPad Prism 4 software.
In vitro assays.
The extent of cytolysis of infected macrophages was determined by measuring the release of lactate dehydrogenase (LDH) in the supernatants of infected macrophages using the CytoTox 96 non-radioactive cytotoxicity assay kit (Promega) as described in the manufacturer's instructions. Samples were read at 490 nm on a VersaMax tunable microplate reader (Molecular Devices). Background release of LDH was calculated using supernatants of uninfected cells, and maximum release of LDH from the complete lysis of uninfected BMMO. The percentage of cell death was estimated by the following formula: [release of LDH from infected cells (A490)/maximum LDH release (A490)]x100.
The amount of IL-10 and IL-12 in the culture supernatants of infected BMMO was assayed using BD OptEIA mouse cytokines kits (BD Pharmingen) and the ELISA was performed in accordance with the manufacturer's instructions. Samples were read at 450 nm on a VersaMax tunable microplate reader with a reference wavelength of 650 nm. Cytokines were quantified by comparison with specific recombinant standards using a log-log fit regression in the SoftMax Pro ELISA analysis software (Molecular Devices). To determine nitrite released by macrophages (as a measure of nitric oxide production), culture supernatants were tested with Griess reagent (Promega) and the absorbance was measured at 520 nm. In all cases standard curves were plotted and samples were tested in triplicate in order to measure statistically significant differences.
In vivo infection in mice with recombinant M. smegmatis.
Five C57BL/6 J female mice per group were each infected by intraperitoneal injection with 2x107 c.f.u. of M. smegmatis strains containing vector only, or expressing PE_PGRS 33, PE_PGRS 16 or PE_PGRS 26, and c.f.u. were determined as previously described (Dheenadhayalan et al., 2006a
) on days 2, 4 and 10. For studying in vivo immune responses following infection with recombinant strains, spleens were removed at day 4 and homogenized in DMEM. The homogenate was treated with RBC lysing Ack buffer (Quality Biological) followed by three washes with incomplete DMEM. Splenocytes were cultured in a 24-well microplate in complete DMEM for 3 days and the supernatants were tested for release of nitrite and cytokines.
Extraction of recombinant proteins in M. smegmatis with the detergent Genapol.
To determine if PE_PGRS proteins are found at the surface of recombinant M. smegmatis strains a method described by Cascioferro et al. (2007)
was used. Bacteria were cultured for 3 days, washed once with 1x PBS, and one half of the pellet (each half contained 10 mg of bacteria) was incubated in 50 µl PG05 buffer containing 0.5 % (v/v) Genapol for 30 min at 50 °C. The other half of the sample was used as a control. Samples were centrifuged twice for 10 min at 4 °C at 6000 g and the supernatant was checked for PE_PGRS protein content by Western blots using the 7C4.IF7 mAb as primary and goat anti-mouse alkaline phosphatase as the secondary antibody and developed with the phosphatase substrate BCIP/NBT (KPL).
Immunizations and aerosol challenge.
C57BL/6 J female mice (five per group) were immunized three times at 3 week intervals with 100 µg each of the pe_pgrs 16, pe_pgrs 26 and pe_pgrs 33 DNA vaccines intramuscularly using vector pJW4303 as a control. For the BCG immunizations, the mice received 1x106 c.f.u. subcutaneously at the beginning of the experiments. Three weeks after the last immunization, mice were challenged for the protection study with approximately 200 c.f.u. of M. tuberculosis Erdman by aerosol. Four weeks later mice were sacrificed and bacterial colonization was determined in spleens and lungs as described previously (Parra et al., 2006
). All animal protocols were approved by the Center for Biologics Evaluation and Research/Food and Drug Administration Institutional Animal Care and Use Committee.
| RESULTS |
|---|
|
|
|---|
|
|
45 %) by day 6 in macrophages infected with Ms-PE_PGRS 33, as previously reported (Dheenadhayalan et al., 2006aSince both reactive nitrogen intermediates and cytokines can control the intracellular fate of mycobacteria in host cells, we measured the levels of nitric oxide (NO) and the cytokines IL-10 and IL-12 following infection of BMMO with the recombinant M. smegmatis strains expressing the PE_PGRS proteins. The highest NO production (33.3 µM) was observed in macrophages infected with Ms-PE_PGRS 16, which was followed by macrophages infected with Ms-PE_PGRS 26 (25 µM) and then by Ms-PE_PGRS 33 (16.7 µM) after 3 days in culture (Fig. 3B). Macrophages infected with Ms-PE_PGRS 16 released the highest amount of IL-12 (2.8 ng ml–1) and the lowest amount of IL-10 (0.32 ng ml–1) at day 3 (Fig. 3C, D). Conversely, macrophages infected with Ms-PE_PGRS 33 released the highest levels of IL-10 (0.68 ng ml–1) and the least IL-12 (1.4 ng ml–1). Infection with Ms-PE_PGRS 26 induced 0.48 ng IL-10 ml–1 and 2.1 ng IL-12 ml–1. The data demonstrate an association between increased levels of NO and IL-12 and decreased survival for the Ms-PE_PGRS 16 strain in macrophages. Conversely, lower levels of NO and IL-12 and increased levels of IL-10 are associated with better survival of the Ms-PEPGRS 33 and Ms-PE_PGRS 26 strains.
In vivo survival and cellular responses to recombinant M. smegmatis strains expressing different M. tuberculosis PE_PGRS proteins following infection of mice
In order to study the fate of recombinant M. smegmatis expressing different PE_PGRS proteins following in vivo infection, we compared the survival of recombinant M. smegmatis expressing each of the three PE_PGRS proteins in comparison to the vector control in mouse tissues. C57BL/6 mice were infected intraperitoneally with 2x107 c.f.u. of each of the recombinant M. smegmatis strains. The relative mRNA expression levels for each PE_PGRS protein expressed by the recombinant strains in mouse organs at day 10 were similar as determined by real-time RT-PCR (Fig. 4A
, inset). As shown in Fig. 4(A)
, there was a fairly rapid clearance of bacteria in the mouse lungs; however, Ms-PE_PGRS 33 at 4.2 log c.f.u. and Ms-PE_PGRS 26 at 3.6 log c.f.u. persisted at higher levels in the lungs at day 4 compared with Ms-PE_PGRS 16 (3 log c.f.u.) and the vector control (2.7 log c.f.u.). Also, significantly higher numbers of Ms-PE_PGRS 33 were found in spleen (3.5 log c.f.u.) and in liver (3 log c.f.u.) in comparison to the vector (2.4 and 2.1 log c.f.u.) at day 10 (Fig. 4B, C
). Persistence of Ms-PE_PGRS 26 was relatively lower than that of Ms-PE_PGRS 33 but significantly greater than that of the vector alone, since Ms-PE_PGRS 26 persisted at 0.5 log c.f.u. higher than the vector in liver and 0.7 log c.f.u. higher in spleen after 10 days of infection. However, Ms-PE_PGRS 16 showed the least persistence: approximately 1.5–2 log c.f.u. less than Ms-PE_PGRS 33 in all three organs and 0.4 and 1 log c.f.u. less in the spleen and liver compared to the vector alone.
|
|
|
|
|
| DISCUSSION |
|---|
|
|
|---|
When comparing previous results obtained using recombinant M. smegmatis strains in in vivo infection experiments with results described in Fig. 4
, we observed that colonization of mouse lung tissues by the recombinant M. smegmatis strain expressing PE_PGRS 33 and the vector control was significantly increased compared to results published earlier (Dheenadhayalan et al., 2006a
). This may be due to the fact that the pe_pgrs genes were cloned in a vector slightly different from that used in the previous study. In general, we have also found that survival of M. smegmatis in lung tissues lasts only 2–4 days, and is more variable than in spleens and liver. For this reason, experiments in mice needed to be repeated a number of times. However, it is important to note that the recombinant M. smegmatis infection data in spleen and liver tissues are reproducible and consistent with the previously published data.
As shown in Fig. 1
, PE_PGRS 16 differs from the typical PE_PGRS protein in that it contains a large C-terminal segment following the PGRS region that contains the characteristic Gly/Ala-rich repeat elements. This could account for the differences observed in our studies in comparison with PE_PGRS 33 and PE_PGRS 26, which share high similarity and contain the more typical PE and PGRS regions connected by a conserved linker region (Brennan & Delogu, 2002
). It is possible that the C-terminal segment found in PE_PGRS 16 directly induces the biological responses observed in our studies, or that it may cause conformational changes that alter the way the protein interacts with host cell factors. In genomic searches using the C-terminal segment of PE_PGRS 16 we have, to date, found no homologous domains of interest that would suggest a function for this unique doman, although interestingly C-terminal domains with approximately 38–40 % homology with PE_PGRS 16 also exist in PE_PGRS 35 and in PE 26 members of the PE family. Further studies are needed to determine the importance of these C-terminal domains for altering responses to PE_PGRS proteins. While characterizing the DNA vaccines used in these studies, we also observed following transfection of macrophages that PE_PGRS 16 is localized differently from PE_PGRS33 and PE_PGRS 26: it occurs as discrete deposits dispersed throughout the cell, whereas PE_PGRS 33 and PE_PGRS 26 show a perinuclear distribution (P. P. Singh and others, unpublished data). This suggests that PE_PGRS 16 may interact with intracellular compartment components differently from PE_PGRS 33 and PE_PGRS 26 and that the antigen could be presented differently to the host immune system.
Expression and microarray studies have demonstrated that a number of pe_pgrs genes are regulated independently under various growth conditions (Voskuil et al., 2004
). In previous studies, we have shown that PE_PGRS 16 and PE_PGRS 26 are inversely regulated, with expression of PE_PGRS 16 increasing after infection of mice or macrophages while the expression of PE_PGRS 26 decreases (Dheenadhayalan et al., 2006b
). In contrast, the expression of PE_PGRS 33 remains fairly constant over time. Interestingly, pe_pgrs 16 belongs to an in vivo-expressed genomic island (Talaat et al., 2004
) that also contains two other pe_pgrs genes, pe_pgrs 17 and pe_pgrs 18, and a mycobacterial persistence regulator mprA which is a two-component response transcriptional regulatory protein. It would be of interest to determine if the mprA system regulates the expression of pe_pgrs 16 and other pe_pgrs genes. Expression of PE_PGRS 16 has also been shown to be significantly upregulated following human brain microvascular endothelial cell invasion by M.tuberculosis strain H37 Rv used as a model of CNS tuberculosis (Jain et al., 2006
). In contrast to our previous findings (Dheenadhayalan et al., 2006b
), Williams et al. (2007)
have shown that expression of M. tuberculosis PE_PGRS 26 is significantly upregulated following induction of sigma factor F, which may help mycobacteria survive under stressful environmental conditions. The differences in host cell responses observed in the present studies using PE_PGRS 16 compared to PE_PGRS 33 and PE_PGRS 26 suggest that regulated expression of different PE_PGRS proteins by M. tuberculosis could affect the fate of the mycobacterial pathogen as well as the response by the host to infection. However, it remains to be determined how increased expression of PE_PGRS 16 in host cells could favour the mycobacteria and, conversely, how decreased expression of PE_PGRS 26 may benefit the bacterium. In fact, the initial data reported here suggest that this expression scenario would favour the host; this is a paradox that remains to be investigated. The ability of PE_PGRS 33 to induce cytolysis and enhance persistence of mycobacteria both in vitro and in vivo has been confirmed in these studies and suggests, as did earlier work using a transposon mutant in PE_PGRS 33 (Brennan et al., 2001
), that expression of this PE_PGRS protein may be critical for maintaining the infectivity of the mycobacterium.
Talarico et al. (2005
, 2008
) have included pe_pgrs 16, pe_pgrs 26 and pe_pgrs 33 in their genetic studies and have shown that significant insertions and deletions occur mostly in the PGRS region of all three pe_pgrs genes in clinical isolates of M. tuberculosis. Most mutations in pe_pgrs 33 did not alter the reading frame whereas numerous frameshifts were observed in the case of pe_pgrs 16 and pe_pgrs 26. These results indicate that alterations in PE_PGRS proteins can occur through mechanisms of genetic recombination as well as via regulation of gene expression that could lead to changes in function and host recognition. These variations could reflect the differences in the ability of the pathogen to persist in the host.
Earlier work by our laboratory and others has shown that a number of PE_PGRS proteins, including PE_PGRS 33 (Delogu et al., 2004
) and PE_PGRS 26 (Banu et al., 2002
), can be found at the bacterial surface. This may be important for a possible role for PE_PGRS proteins in interacting with host cells to promote infectivity, for interacting with the host immune system or as important structural components of the cell wall (Brennan et al., 2004
). Here we have shown that PE_PGRS 16, PE_PGRS 26 and PE_PGRS 33 can be found at the cell surface when expressed in M. smegmatis. The presence of PE_PGRS antigens at the surface of mycobacteria also suggests that they could be targets for new vaccines and drugs. Our previous study (Delogu & Brennan, 2001
) showed that following immunization with PE_PGRS 33 DNA vaccine, a significant humoral response was observed against recombinant PE_PGRS 33 and that the antibody response was directed against the Gly/Ala-rich PGRS domain. Moreover, this study showed that PE_PGRS 33 delivered as a DNA vaccine did not show protection in the mouse TB challenge model. In the present study, we extended our investigation to assess the potential of PE_PGRS 16 and PE_PGRS 26 DNA vaccines to show protection in the mouse TB challenge model, particularly since PE_PGRS 16 elicited different cellular responses, including the release of IL12 (see Figs 3 and 5
), and contains an unusual C-terminal domain. Our results indicate that when given as DNA vaccines and studied in the mouse TB aerosol challenge model, none of the three PE_PGRS vaccines protect mice against aerosol challenge with the virulent M. tuberculosis Erdman strain as measured by colonization of the lungs and spleens of mice 30 days after challenge. In contrast, we have previously shown that a PE vaccine can protect in this TB model (Parra et al., 2006
). Interestingly, for mice immunized with pe_pgrs 33 and to some extent pe_pgrs 26, disease was worsened as indicated by increased colonization of lungs in mice vaccinated with these PE_PGRS vaccines. In our in vitro studies, recombinant M. smegmatis expressing PE_PGRS 33 and PE_PGRS 26 survived better in macrophages that made less IL-12 and more IL-10 compared to M. smegmatis carrying the vector only. These data suggest that certain PE_PGRS antigens may induce Th2-like responses. This is supported by the observation that immunization with all three DNA vaccines induces antibodies that also show cross-reactivity with the PGRS domain of the three PE_PGRS antigens. However, expression of PE_PGRS 16 in our study induced release of IL-12, which is a key mediator of Th1 differentiation; this suggests that different PE_PGRS proteins may also elicit variable immune responses.
In the experiments described here, we demonstrate that the intracellular expression of different PE_PGRS proteins can alter the host cell environment, which can have consequences for both the mycobacteria and the host cells. Further studies are needed to determine why host cell responses to PE_PGRS 16 differ from those of PE_PGRS 33 and PE_PGRS 26. More generally, it will be of interest to determine how the expression of individual PE_PGRS genes is regulated in the host and what role this regulated control of PE_PGRS family members may have on the pathogenesis caused by M. tuberculosis.
|
| ACKNOWLEDGEMENTS |
|---|
Edited by: M. Daffé
| REFERENCES |
|---|
|
|
|---|
Banu, S., Honore, N., Saint-Joanis, B., Philpott, D., Prévost, M. C. & Cole, S. T. (2002). Are the PE-PGRS proteins of Mycobacterium tuberculosis variable surface antigens? Mol Microbiol 44, 9–19.[CrossRef][Medline]
Basu, S., Pathak, S. K., Banerjee, A., Pathak, S., Bhattacharyya, A., Yang, Z., Talarico, S., Kundu, M. & Basu, J. (2007). Execution of macrophage apoptosis by PE_PGRS33 of Mycobacterium tuberculosis is mediated by Toll-like receptor 2-dependent release of tumor necrosis factor. J Biol Chem 282, 1039–1050.
Brennan, M. J. & Delogu, G. (2002). The PE multigene family: a molecular mantra for mycobacteria. Trends Microbiol 10, 246–249.[CrossRef][Medline]
Brennan, M. J., Delogu, G., Chen, Y., Bardarov, S., Kriakov, J., Alavi, M. & Jacobs, W. R., Jr (2001). Evidence that mycobacterial PE_PGRS proteins are cell surface constituents that influence interactions with other cells. Infect Immun 69, 7326–7333.
Brennan, M. J., Espitia, C. & Gey van Pittius, N. (2004). The PE and PPE multigene families of Mycobacterium tuberculosis. In Tuberculosis, 2nd edn, pp. 513–525. Edited by S. Cole, D. N. McMurray, K. Eisenach, B. Gicquel & W. R. Jacobs. Washington, DC: American Society for Microbiology.
Cascioferro, A., Delogu, G., Colone, M., Sali, M., Stringaro, A., Arancia, G., Fadda, G., Palu, G. & Mangenelli, R. (2007). PE is a functional domain responsible for protein translocation and localization on mycobacterial cell wall. Mol Microbiol 66, 1536–1547.[Medline]
Chen, M., Gan, H. & Remold, H. G. (2006). A mechanism of virulence: virulent Mycobacterium tuberculosis strain H37Rv but not attenuated H37Ra causes significant mitochondrial inner membrane disruption in macrophages leading to necrosis. J Immunol 176, 3707–3716.
Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S. V., Eiglmeier, K., Gas, S. & other authors (1998). Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393, 537–544.[CrossRef][Medline]
Delogu, G. & Brennan, M. J. (2001). Comparative immune response to PE and PE_PGRS antigens of Mycobacterium tuberculosis. Infect Immun 69, 5606–5611.
Delogu, G., Pusceddu, C., Bua, A., Fadda, G., Brennan, M. J. & Zanetti, S. (2004). Rv1818c-encoded PE_PGRS protein of Mycobacterium tuberculosis is surface exposed and influences bacterial cell structure. Mol Microbiol 52, 725–733.[CrossRef][Medline]
Delogu, G., Sanguinetti, M., Pusceddu, C., Bua, A., Brennan, M. J., Zanetti, S. & Fadda, G. (2006). PE_PGRS proteins are differentially expressed by Mycobacterium tuberculosis in host tissues. Microbes Infect 8, 2061–2067.[CrossRef][Medline]
Dheenadhayalan, V., Delogu, G. & Brennan, M. J. (2006a). Expression of the PE_PGRS 33 protein in M. smegmatis triggers necrosis in macrophages and enhanced mycobacterial survival. Microbes Infect 8, 262–272.[CrossRef][Medline]
Dheenadhayalan, V., Delogu, G., Sanguinetti, M., Fadda, G. & Brennan, M. J. (2006b). Variable expression patterns of Mycobacterium tuberculosis PE_PGRS genes: evidence that PE_PGRS16 and PE_PGRS26 are inversely regulated in vivo. J Bacteriol 188, 3721–3725.
Espitia, C., Laclette, J. P., Mondragón-Palomino, M., Amador, A., Campuzano, J., Martens, A., Singh, M., Cicero, R., Zhang, Y. & Moreno, C. (1999). The PE-PGRS glycine-rich proteins of Mycobacterium tuberculosis: a new family of fibronectin-binding proteins? Microbiology 145, 3487–3495.
Flores, J. & Espitia, C. (2003). Differential expression of PE and PE_PGRS genes in Mycobacterium tuberculosis strains. Gene 318, 75–81.[CrossRef][Medline]
Heinz, C. & Niederweis, M. (2000). Selective extraction and purification of a mycobacterial outer membrane protein. Anal Biochem 285, 113–120.[CrossRef][Medline]
Jain, S. K., Satyaseela, M. P., Lamichhane, G., Kim, K. S. & Bishai, W. R. (2006). Mycobacterium tuberculosis invasion and traversal across an in vivo human blood-brain barrier as a pathogenic mechanism for central nervous system tuberculosis. J Infect Dis 193, 1287–1295.[CrossRef][Medline]
Parra, M., Cadieux, N., Pickett, T., Dheenadhayalan, V. & Brennan, M. J. (2006). A PE protein expressed by Mycobacterium avium is an effective T-cell immunogen. Infect Immun 74, 786–789.
Pfaffl, M. W. (2001). A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29, e45
Ramakrishnan, L., Federspiel, N. A. & Falkow, S. (2000). Granuloma-specific expression of Mycobacterium virulence proteins from the glycine-rich PE-PGRS family. Science 288, 1436–1439.
Talaat, A. M., Lyons, R., Howard, S. T. & Johnston, S. A. (2004). The temporal expression profile of Mycobacterium tuberculosis infection in mice. Proc Natl Acad Sci U S A 101, 4602–4607.
Talarico, S., Cave, M. D., Marrs, C. F., Foxman, B., Zhang, L. & Yang, Z. (2005). Variation of the Mycobacterium tuberculosis PE_PGRS33 gene among clinical isolates. J Clin Microbiol 43, 4954–4960.
Talarico, S., Zhang, L., Marrs, C. F., Foxman, B., Cave, M. D., Brennan, M. J. & Yang, Z. (2008). Mycobacterium tuberculosis PE_PGRS 16 and PE_PGRS 26 genetic polymorphism among clinical isolates. Tuberculosis (Edinb) 88, 283–294.[CrossRef][Medline]
Voskuil, M. I., Schnappinger, D., Rutherford, R., Liu, Y. & Schoolnick, G. K. (2004). Regulation of the Mycobacterium tuberculosis PE/PPE genes. Tuberculosis (Edinb) 84, 256–262.[CrossRef][Medline]
Williams, E. P., Lee, J. H., Bishai, W. R., Colantuoni, C. & Karakousis, P. C. (2007). Mycobacterium tuberculosis Sig F regulates genes encoding cell wall associated proteins and directly regulates the transcriptional regulatory gene phoY1. J Bacteriol 189, 4234–4242.
Received 24 April 2008;
revised 8 July 2008;
accepted 23 July 2008.
This article has been cited by other articles:
![]() |
O. Chacon, L. E. Bermudez, D. K. Zinniel, H. K. Chahal, R. J. Fenton, Z. Feng, K. Hanford, L. G. Adams, and R. G. Barletta Impairment of D-alanine biosynthesis in Mycobacterium smegmatis determines decreased intracellular survival in human macrophages Microbiology, May 1, 2009; 155(5): 1440 - 1450. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | MICROBIOLOGY | J GEN VIROL |
| J MED MICROBIOL | ALL SGM JOURNALS | |